Literature DB >> 9605066

Cardiopulmonary bypass is associated with early allograft dysfunction but not death after double-lung transplantation.

J S Gammie1, J Cheul Lee, S M Pham, R J Keenan, R J Weyant, B G Hattler, B P Griffith.   

Abstract

OBJECTIVES: To assess the effect of cardiopulmonary bypass on allograft function and recipient survival in double-lung transplantation.
METHODS: Retrospective review of 94 double-lung transplantations.
RESULTS: Cardiopulmonary bypass was used in 37 patients (CPB); 57 transplantations were accomplished without bypass (no-CPB). Bypass was routinely used for patients with pulmonary hypertension (n = 27) and for two recipients undergoing en bloc transplantation. Cardiopulmonary bypass was required in eight (12.3%) of the remaining 65 patients. Mean ischemic time was longer in the CPB group (346 vs 315 minutes, p = 0.04). The CPB group required more perioperative blood (11.4 vs 6.0 units, p = 0.01). Allograft function, assessed by the arterial/alveolar oxygen tension ratio, was better in the no-CPB group at 12 and 24 hours after operation (0.54 vs 0.39 at 12 hours, p = 0.002; and 0.63 vs 0.38 at 24 hours, p = 0.001). The CPB group had more severe pulmonary infiltrates at both 1 and 24 hours (p = 0.005). Diffuse alveolar damage was more common in the CPB group (69% vs 35%, p = 0.002). Median duration of intubation was longer in the CPB group (10 days) than in the no-CPB group (2 days, p = 0.002). The 30-day mortality rate (13.5% vs 7.0% in the CPB and no-CPB groups) and 1-year survival (65% vs 67%, CPB and no-CPB) were not significantly different.
CONCLUSIONS: In the absence of pulmonary hypertension, cardiopulmonary bypass is only occasionally necessary in double-lung transplantation. Bypass is associated with substantial early allograft dysfunction after transplantation.

Entities:  

Mesh:

Year:  1998        PMID: 9605066     DOI: 10.1016/s0022-5223(98)70396-4

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

1.  Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass for Lung Transplantation.

Authors:  Christopher A Heid; Mitri K Khoury; Kayla Maaraoui; Charles Liu; Matthias Peltz; Michael A Wait; W Steves Ring; Lynn C Huffman
Journal:  J Surg Res       Date:  2020-06-26       Impact factor: 2.192

Review 2.  Established and potential predictors of blood loss during lung transplant surgery.

Authors:  Pascal Oechslin; Marco P Zalunardo; Ilhan Inci; Martin Schlaepfer; Bastian Grande
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 3.  New horizons of non-emergent use of extracorporeal membranous oxygenator support.

Authors:  George Makdisi; Peter B Makdisi; I-Wen Wang
Journal:  Ann Transl Med       Date:  2016-02

4.  Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-analysis.

Authors:  Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; Alexis A Svokos; Konstantina A Svokos; Dimitris Zacharoulis
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-09-16

5.  Advances in lung transplantation.

Authors:  V G Valentine; P M McFadden; J L Ochsner
Journal:  Ochsner J       Date:  1999-01

6.  Weight loss prior to lung transplantation is associated with improved survival.

Authors:  Satish Chandrashekaran; Cesar A Keller; Walter K Kremers; Steve G Peters; Matthew A Hathcock; Cassie C Kennedy
Journal:  J Heart Lung Transplant       Date:  2014-11-17       Impact factor: 10.247

7.  Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

Authors:  Rupal J Shah; Joshua M Diamond; Edward Cantu; James C Lee; David J Lederer; Vibha N Lama; Jonathan Orens; Ann Weinacker; David S Wilkes; Sangeeta Bhorade; Keith M Wille; Lorraine B Ware; Scott M Palmer; Maria Crespo; A Russell Localio; Ejigayehu Demissie; Steven M Kawut; Scarlett L Bellamy; Jason D Christie
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

8.  Obesity and underweight are associated with an increased risk of death after lung transplantation.

Authors:  David J Lederer; Jessie S Wilt; Frank D'Ovidio; Matthew D Bacchetta; Lori Shah; Shankari Ravichandran; Jenny Lenoir; Brenda Klein; Joshua R Sonett; Selim M Arcasoy
Journal:  Am J Respir Crit Care Med       Date:  2009-07-16       Impact factor: 21.405

9.  Clinical risk factors for primary graft dysfunction after lung transplantation.

Authors:  Joshua M Diamond; James C Lee; Steven M Kawut; Rupal J Shah; A Russell Localio; Scarlett L Bellamy; David J Lederer; Edward Cantu; Benjamin A Kohl; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Joshua Sonett; Keith Wille; Jonathan Orens; Ashish S Shah; Ann Weinacker; Selim Arcasoy; Pali D Shah; David S Wilkes; Lorraine B Ware; Scott M Palmer; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2013-01-10       Impact factor: 21.405

10.  Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.

Authors:  Joshua M Diamond; Mary K Porteous; Edward Cantu; Nuala J Meyer; Rupal J Shah; David J Lederer; Steven M Kawut; James Lee; Scarlett L Bellamy; Scott M Palmer; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Keith Wille; Jonathan Orens; Pali D Shah; Ann Weinacker; David Weill; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.